Tag:
Pfizer
Latest Headlines
Latest Headlines
UnitedHealth, Coventry scrutinized for favoring brand-name drug
UnitedHealthcare and Coventry are being investigated for their role in Pfizer's attempt to block new generic competition in favor of its cholesterol-lowering drug Lipitor. Since Lipitor lost its
UnitedHealth to price Lipitor cheaper than generics
UnitedHealthcare will encourage its members to continue using Pfizer's cholesterol-lowering drug Lipitor instead of the generic version after Lipitor loses patent protection at the end of the month.
Medical data mining can predict adverse drug events
Researchers for the RAND Corp. have determined that it's possible to mine medical literature to find out whether studies involving particular medications can predict patient harm from those drugs.
SPOTLIGHT: Holder says fraud crackdown paying off
Attorney General Eric Holder says the healthcare fraud crackdown the U.S. Justice Department and the Department of Health and Human Services have undertaken is beginning to pay off, the Associated
Surprising facts about pharma's best paid pill-pushing docs
When doctors discuss what a medication can do, it confers a veneer of respectability on the drug company's marketing. But a ProPublica investigation uncovered that fewer than half of the best paid
Get a prescription online without ever seeing a doc
A recent article in Forbes reports how patients in Britain are able to go to least a dozen websites for online consultations with doctors they've never met and have physicians prescribe medications.
Medical educators in Pennsylvania received at least $10 million from drug companies in 2009
Conflict-of-interest allegations aside, several Pittsburgh-area doctors and nurse educators are insisting that their work is not compromised despite data showing they were paid roughly $3.5 million
Four Blues plans to sue Pfizer and its execs re: Off-label med use and illegal kickbacks
Chicago-based Health Care Service Corp. (HCSC) and its four Blue Cross Blue Shield plans in Texas, Illinois, New Mexico and Oklahoma have filed a lawsuit over the off-label use of three costly drugs
Big firms disappoint with weak mobile health efforts at Health 2.0 Europe
Much like its more-established counterpart in the U.S., the first-ever Health 2.0 Europe conference, held earlier this month, was heavy on mobile technologies. Though we would have loved to be able
Lilly exec will explore links to industry at Harvard
An executive with Eli Lilly has accepted a job with Harvard Medical School that will entail studying the relationship between the school's researchers and the pharmaceutical industry. William Chin,
